ADVB Advanced Biomed Inc Total Debt to Capital

ADVB (Advanced Biomed Inc) - company brandmark

Advanced Biomed Inc (ADVB) aims for the global distribution of microfluidic systems to combat oncology. Company management is focused on validating test efficacy to ensure their inclusion in standard medical protocols. The business is currently developing high-precision tumor screening tools, and the individual debt-to-equity ratio stands at 0.08. This chart illustrates the exchange price action based on this metric.

Debt to Equity Ratio: Advanced Biomed Inc. (ADVB) for 03/07/2025 - 10/28/2026

Comprehensive metric breakdowns and analytics for Advanced Biomed (ADVB)

- price and consensus price forecast:
Stock Price Advanced Biomed Inc.|ADVB - Consensus Target
- market capitalization data:
Market Capitalization Advanced Biomed|ADVB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Advanced Biomed|ADVB - Accounting Capitalization|Market Capitalization to Book Value Ratio advanbiomed.com|ADVB - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Advanced Biomed Inc|ADVB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Advanced Biomed Inc.|ADVB - Aggregate Debt Obligations|Debt to Book Value Advanced Biomed
Comprehensive company analysis:ADVB - Advanced Biomed Inc
Product sample of Advanced Biomed Inc.

This ratio determines the share of borrowed funds within the financing structure, comparing total liabilities to net assets to assess financial stability. The debt-to-equity dynamics are critical for Advanced Biomed Inc. (ADVB), as liquidity shortages and losses incurred during the development of diagnostic platforms make the business highly dependent on external leverage.

Main competitors

Total Debt to Capital ONC|Total Debt to Equity Ratio Halozyme Therapeutics, Inc.|Total Debt to Capital RVMD|Total Debt to Capital AAPG (Ascentage Pharma Corp)|CGON - Debt to Equity|Debt to Equity Ratio urogen.com URGN|BCAX: Total Debt to Capital|PSNL - Total Debt to Equity Ratio|Total Debt to Capital ERAS|DCTH (Delcath Corp) - Debt to Capital|YMAB - Debt to Equity|All Debt to Shareholders' Equity Ratio aurabiosciences.com (AURA)|Candel Therapeutics (CADL) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio Accuray Inc (ARAY)|SELLAS Life Sciences Group - Total Debt to Capital|ACTU - Total Debt to Equity Ratio|Citius Oncology, Inc. - Total Debt to Equity Ratio|HURA: Total Debt to Capital|Debt to Equity Protara Therapeutics, Inc. TARA|Fate Therapeutics Inc (FATE) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital WHWK (Aadi Bioscience, Inc.)|Debt to Capital TScan|Total Debt to Capital CSBR|Total Debt to Capital xbiotech.com (XBIT)|CVM - Total Debt to Capital|OSTX - Debt to Equity Ratio|RADX - Total Debt to Equity Ratio|ARTV - Debt to Equity|ANL: Total Debt to Capital|VERU (verupharma.com) - Total Debt to Capital|Debt to Equity Tempest Therapeutics, Inc. (TPST)|Debt to Equity Ratio Xilio|Total Debt to Capital RENB (Renovaro Inc.)|Total Debt to Equity Ratio muraloncology.com (MURA)|KAPA: Total Debt to Capital|Debt to Capital OnKure Therapeutics, Inc. OKUR|CytoMed (GDTC) - Total Debt to Capital|Curis, Inc. (CRIS) - Debt to Equity Ratio|Total Debt to Equity Ratio apollomicsinc.com APLM|Tharimmune Corporation (THAR) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital Genprex, Inc.|Debt to Equity Calidi Bio|SBFM (Sunshine Biopharma, Inc.) - Total Debt to Capital|Total Debt to Capital Coefficient XBIO (xeneticbio.com)|SLRX: Debt to Equity|Kitov Pharma - Debt to Capital|AONC: Debt to Equity|BGNE - Total Debt to Equity Ratio|Total Debt to Capital CKPT|elevationoncology.com (ELEV) - Debt to Capital|Total Debt to Capital iCAD Inc. (ICAD)|Debt to Equity Ratio Ikena (IKNA)|Notable Labs, Ltd. (NTBL) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio viracta.com (VIRX)|Total Debt to Capital MOR|NAYA Biosciences Inc - Total Debt to Capital Coefficient|Ascentage Pharma Group Ltd (AAPGV) - Debt to Equity